CN101675066A - 抑制清道夫受体-a和增强对抗原的免疫应答的方法 - Google Patents

抑制清道夫受体-a和增强对抗原的免疫应答的方法 Download PDF

Info

Publication number
CN101675066A
CN101675066A CN200880012072A CN200880012072A CN101675066A CN 101675066 A CN101675066 A CN 101675066A CN 200880012072 A CN200880012072 A CN 200880012072A CN 200880012072 A CN200880012072 A CN 200880012072A CN 101675066 A CN101675066 A CN 101675066A
Authority
CN
China
Prior art keywords
cell
antigen
individuality
mouse
medicine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200880012072A
Other languages
English (en)
Chinese (zh)
Inventor
王向阳
J·萨布杰克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Health Research Inc
Original Assignee
Health Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Health Research Inc filed Critical Health Research Inc
Publication of CN101675066A publication Critical patent/CN101675066A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN200880012072A 2007-04-16 2008-04-16 抑制清道夫受体-a和增强对抗原的免疫应答的方法 Pending CN101675066A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US92362807P 2007-04-16 2007-04-16
US60/923,628 2007-04-16
PCT/US2008/060479 WO2008131006A2 (en) 2007-04-16 2008-04-16 Method for inhibiting scavenger receptor-a and increasing immune response to antigens

Publications (1)

Publication Number Publication Date
CN101675066A true CN101675066A (zh) 2010-03-17

Family

ID=39853929

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880012072A Pending CN101675066A (zh) 2007-04-16 2008-04-16 抑制清道夫受体-a和增强对抗原的免疫应答的方法

Country Status (6)

Country Link
US (2) US8133875B2 (https=)
EP (1) EP2147011A4 (https=)
JP (1) JP5565906B2 (https=)
CN (1) CN101675066A (https=)
CA (1) CA2684278C (https=)
WO (1) WO2008131006A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102844050A (zh) * 2010-02-19 2012-12-26 康奈尔大学 自身免疫性脱髓鞘疾病及其它自身免疫疾病或炎性疾病的治疗方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000078145A1 (en) 1999-06-24 2000-12-28 Smithkline Beecham Corporation Macrophage scavenger receptor antagonists
GB9927328D0 (en) * 1999-11-18 2000-01-12 Lorantis Ltd Immunotherapy
WO2003042246A2 (en) * 2001-11-14 2003-05-22 Lorantis Limited Inhibitors of the notch signalling pathway for use in the treatment of cancer
WO2004080385A2 (en) * 2003-03-12 2004-09-23 Rappaport Family Institute For Research In The Medical Sciences Compositions and methods for diagnosing and treating an inflammation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HARSHYNE 等: "A Role for Class A Scavenger Receptor in Dendritic Cell Nibbling from Live Cells", 《THE JOURNAL OF IMMUNOLOGY》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102844050A (zh) * 2010-02-19 2012-12-26 康奈尔大学 自身免疫性脱髓鞘疾病及其它自身免疫疾病或炎性疾病的治疗方法
US9375473B2 (en) 2010-02-19 2016-06-28 Cornell Research Foundation, Inc. Method to treat autoimmune demyelinating diseases and other autoimmune or inflammatory diseases

Also Published As

Publication number Publication date
EP2147011A4 (en) 2012-07-18
CA2684278A1 (en) 2008-10-30
US8314076B2 (en) 2012-11-20
US8133875B2 (en) 2012-03-13
EP2147011A2 (en) 2010-01-27
WO2008131006A2 (en) 2008-10-30
CA2684278C (en) 2018-06-12
US20080254072A1 (en) 2008-10-16
JP2010526034A (ja) 2010-07-29
JP5565906B2 (ja) 2014-08-06
US20120156223A1 (en) 2012-06-21
WO2008131006A3 (en) 2008-12-24

Similar Documents

Publication Publication Date Title
US11597934B2 (en) Methods and compositions for reducing immunosuppression by tumor cells
Courau et al. TGF-β and VEGF cooperatively control the immunotolerant tumor environment and the efficacy of cancer immunotherapies
Nelson et al. Natural killer T cell immunotherapy combined with IL-15-expressing oncolytic virotherapy and PD-1 blockade mediates pancreatic tumor regression
CN101340927A (zh) TGF-β1抑制性多肽在制备免疫反应调节剂上的用途
EA016168B1 (ru) Способ получения т-клеточной популяции и ее применение
CN106574241A (zh) 癌症免疫疗法组合物和方法
CN108342363A (zh) 共表达抗msln嵌合抗原受体和免疫检查点抑制分子的转基因淋巴细胞及其用途
KR20150046787A (ko) 암 줄기세포에서 발현하는 분자를 타깃으로 하는 암 진단 및 치료 방법
WO2010079833A1 (ja) 新規癌抗原ｅＥＦ２
US20260035696A1 (en) Combination treatment for cancer
US20230046425A1 (en) Immunotherapy for direct reprogramming of cancer cells into immune cells/antigen presenting cells/dendritic cells
Terasaki et al. Mitochondrial transfer from immune to tumor cells enables lymph node metastasis
Mateus-Tique et al. Armored macrophage-targeted CAR-T cells reset and reprogram the tumor microenvironment and control metastatic cancer growth
US9795660B2 (en) Id-protein targeted tumor cell vaccine
US12329809B2 (en) Cellular adjuvants for viral infection
CN101675066A (zh) 抑制清道夫受体-a和增强对抗原的免疫应答的方法
Li et al. The Immunotherapeutic Effect of SIRPα‐Silenced DCs against Cervical Cancer
Braun et al. In vivo silencing of A20 via TLR9-mediated targeted SiRNA delivery potentiates antitumor immune response
Free Emerging cell therapies in the vasculitis field
US20140105885A1 (en) Method for Inhibiting Scavenger Receptor-A and Increasing Immune Response to Antigens
Wang et al. A novel immunogene therapy to cancer with high tumor selectivity and safety
HK1140491A (en) Method for inhibiting scavenger receptor-a and increasing immune response to antigens
Xia Cytotoxicity of T cells induced by recoverin-based fusion protein against tumor cells
Eberhardt et al. Signaling and transcriptional Regulation in Immune Cells
Muniz-Bongers Matrix Metalloproteinase-2 and Toll-like Receptors Modulate Immune Responses in the Tumor Microenvironment

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1140491

Country of ref document: HK

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20100317

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1140491

Country of ref document: HK